{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:55:06Z","timestamp":1790481306803,"version":"4.1.0"},"reference-count":62,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"American Parkinson\u2019s Disease Association (XM)","award":["R01 NS107318 (XM)"],"award-info":[{"award-number":["R01 NS107318 (XM)"]}]},{"name":"American Parkinson\u2019s Disease Association (XM)","award":["R01 AG073291 (XM)"],"award-info":[{"award-number":["R01 AG073291 (XM)"]}]},{"name":"American Parkinson\u2019s Disease Association (XM)","award":["R01 AG071820 (XM)"],"award-info":[{"award-number":["R01 AG071820 (XM)"]}]},{"name":"American Parkinson\u2019s Disease Association (XM)","award":["R21 NS125559 (XM)"],"award-info":[{"award-number":["R21 NS125559 (XM)"]}]},{"name":"American Parkinson\u2019s Disease Association (XM)","award":["RF1 NS125592 (XM)"],"award-info":[{"award-number":["RF1 NS125592 (XM)"]}]},{"name":"American Parkinson\u2019s Disease Association (XM)","award":["PF-JFA-1933 (XM)"],"award-info":[{"award-number":["PF-JFA-1933 (XM)"]}]},{"name":"American Parkinson\u2019s Disease Association (XM)","award":["2019-MSCRFD-4292 (XM)"],"award-info":[{"award-number":["2019-MSCRFD-4292 (XM)"]}]},{"name":"Parkinson\u2019s Foundation the Stanley Fahn Junior Faculty Award","award":["R01 NS107318 (XM)"],"award-info":[{"award-number":["R01 NS107318 (XM)"]}]},{"name":"Parkinson\u2019s Foundation the Stanley Fahn Junior Faculty Award","award":["R01 AG073291 (XM)"],"award-info":[{"award-number":["R01 AG073291 (XM)"]}]},{"name":"Parkinson\u2019s Foundation the Stanley Fahn Junior Faculty Award","award":["R01 AG071820 (XM)"],"award-info":[{"award-number":["R01 AG071820 (XM)"]}]},{"name":"Parkinson\u2019s Foundation the Stanley Fahn Junior Faculty Award","award":["R21 NS125559 (XM)"],"award-info":[{"award-number":["R21 NS125559 (XM)"]}]},{"name":"Parkinson\u2019s Foundation the Stanley Fahn Junior Faculty Award","award":["RF1 NS125592 (XM)"],"award-info":[{"award-number":["RF1 NS125592 (XM)"]}]},{"name":"Parkinson\u2019s Foundation the Stanley Fahn Junior Faculty Award","award":["PF-JFA-1933 (XM)"],"award-info":[{"award-number":["PF-JFA-1933 (XM)"]}]},{"name":"Parkinson\u2019s Foundation the Stanley Fahn Junior Faculty Award","award":["2019-MSCRFD-4292 (XM)"],"award-info":[{"award-number":["2019-MSCRFD-4292 (XM)"]}]},{"name":"Maryland Stem Cell Research Foundation Discovery Award","award":["R01 NS107318 (XM)"],"award-info":[{"award-number":["R01 NS107318 (XM)"]}]},{"name":"Maryland Stem Cell Research Foundation Discovery Award","award":["R01 AG073291 (XM)"],"award-info":[{"award-number":["R01 AG073291 (XM)"]}]},{"name":"Maryland Stem Cell Research Foundation Discovery Award","award":["R01 AG071820 (XM)"],"award-info":[{"award-number":["R01 AG071820 (XM)"]}]},{"name":"Maryland Stem Cell Research Foundation Discovery Award","award":["R21 NS125559 (XM)"],"award-info":[{"award-number":["R21 NS125559 (XM)"]}]},{"name":"Maryland Stem Cell Research Foundation Discovery Award","award":["RF1 NS125592 (XM)"],"award-info":[{"award-number":["RF1 NS125592 (XM)"]}]},{"name":"Maryland Stem Cell Research Foundation Discovery Award","award":["PF-JFA-1933 (XM)"],"award-info":[{"award-number":["PF-JFA-1933 (XM)"]}]},{"name":"Maryland Stem Cell Research Foundation Discovery Award","award":["2019-MSCRFD-4292 (XM)"],"award-info":[{"award-number":["2019-MSCRFD-4292 (XM)"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Parkinson\u2019s Disease (PD) is a neurodegenerative disease characterized by the progressive loss of dopaminergic neurons of the substantia nigra pars compacta with a reduction in dopamine concentration in the striatum. It is a substantial loss of dopaminergic neurons that is responsible for the classic triad of PD symptoms, i.e., resting tremor, muscular rigidity, and bradykinesia. Several current therapies for PD may only offer symptomatic relief and do not address the underlying neurodegeneration of PD. The recent developments in cellular reprogramming have enabled the development of previously unachievable cell therapies and patient-specific modeling of PD through Induced Pluripotent Stem Cells (iPSCs). iPSCs possess the inherent capacity for pluripotency, allowing for their directed differentiation into diverse cell lineages, such as dopaminergic neurons, thus offering a promising avenue for addressing the issue of neurodegeneration within the context of PD. This narrative review provides a comprehensive overview of the effects of dopamine on PD patients, illustrates the versatility of iPSCs and their regenerative abilities, and examines the benefits of using iPSC treatment for PD as opposed to current therapeutic measures. In means of providing a treatment approach that reinforces the long-term survival of the transplanted neurons, the review covers three supplementary avenues to reinforce the potential of iPSCs.<\/jats:p>","DOI":"10.3390\/pharmaceutics15122656","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T03:54:37Z","timestamp":1700625277000},"page":"2656","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cell Therapy for Parkinson\u2019s Disease"],"prefix":"10.3390","volume":"15","author":[{"given":"Surabhi","family":"Shastry","sequence":"first","affiliation":[{"name":"Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA"},{"name":"Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junkai","family":"Hu","sequence":"additional","affiliation":[{"name":"Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA"},{"name":"Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6215-4959","authenticated-orcid":false,"given":"Mingyao","family":"Ying","sequence":"additional","affiliation":[{"name":"Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA"},{"name":"Hugo W. Moser Research Institute at Kennedy Krieger, Baltimore, MD 21205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6587-556X","authenticated-orcid":false,"given":"Xiaobo","family":"Mao","sequence":"additional","affiliation":[{"name":"Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA"},{"name":"Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA"},{"name":"Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD 21218, USA"},{"name":"Department of Materials Science and Engineering, Johns Hopkins University, Baltimore, MD 21218, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/msj.20006","article-title":"Translational experimental therapeutics: The translation of laboratory-based discovery into disease-related therapy","volume":"74","author":"Kieburtz","year":"2007","journal-title":"Mt. Sinai J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pneurobio.2013.04.004","article-title":"Mitochondrial dysfunction and oxidative stress in Parkinson\u2019s disease","volume":"106\u2013107","author":"Subramaniam","year":"2013","journal-title":"Prog. Neurobiol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Stoker, T.B., and Greenland, J.C. (2018). Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects, Codon Publications.","DOI":"10.15586\/codonpublications.parkinsonsdisease.2018"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"a009621","DOI":"10.1101\/cshperspect.a009621","article-title":"Functional neuroanatomy of the basal ganglia","volume":"2","author":"Lanciego","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_5","first-page":"504","article-title":"Parkinson\u2019s Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis","volume":"40","author":"DeMaagd","year":"2015","journal-title":"Pharm. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Stoker, T.B., and Greenland, J.C. (2018). Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects, Codon Publications.","DOI":"10.15586\/codonpublications.parkinsonsdisease.2018"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/WNF.0b013e318065b088","article-title":"Optimizing long-term therapy for Parkinson disease: Levodopa, dopamine agonists, and treatment-associated dyskinesia","volume":"31","author":"Stacy","year":"2008","journal-title":"Clin. Neuropharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41582-018-0128-2","article-title":"Deep brain stimulation: Current challenges and future directions","volume":"15","author":"Lozano","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.tins.2013.06.003","article-title":"Advances in the pharmacological treatment of Parkinson\u2019s disease: Targeting neurotransmitter systems","volume":"36","author":"Brichta","year":"2013","journal-title":"Trends Neurosci."},{"key":"ref_10","first-page":"255","article-title":"Levodopa in the treatment of Parkinson\u2019s disease: Current status and new developments","volume":"3","author":"Salat","year":"2013","journal-title":"J. Park. Dis."},{"key":"ref_11","first-page":"9832839","article-title":"Pathophysiology of Motor Dysfunction in Parkinson\u2019s Disease as the Rationale for Drug Treatment and Rehabilitation","volume":"2016","author":"Magrinelli","year":"2016","journal-title":"Parkinsons Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41591-021-01257-1","article-title":"Autologous transplant therapy alleviates motor and depressive behaviors in parkinsonian monkeys","volume":"27","author":"Tao","year":"2021","journal-title":"Nat. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4103\/aian.AIAN_239_17","article-title":"Levodopa-induced Dyskinesia: Clinical Features, Pathophysiology, and Medical Management","volume":"20","author":"Pandey","year":"2017","journal-title":"Ann. Indian Acad Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1227\/00006123-199412000-00016","article-title":"Bilateral chronic electrostimulation of ventroposterolateral pallidum: A new therapeutic approach for alleviating all parkinsonian symptoms","volume":"35","author":"Siegfried","year":"1994","journal-title":"Neurosurgery"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0140-6736(95)90062-4","article-title":"Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation","volume":"345","author":"Limousin","year":"1995","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/mdc3.12592","article-title":"Challenges in PD Patient Management After DBS: A Pragmatic Review","volume":"5","author":"Rossi","year":"2018","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"688760","DOI":"10.3389\/fneur.2021.688760","article-title":"Short- and Long-Term Effects of DBS on Gait in Parkinson\u2019s Disease","volume":"12","author":"Brozova","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/s41586-020-2388-4","article-title":"Reversing a model of Parkinson\u2019s disease with in situ converted nigral neurons","volume":"582","author":"Qian","year":"2020","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6743","DOI":"10.3390\/molecules15106743","article-title":"Stem cells for the treatment of neurodegenerative diseases","volume":"15","author":"Wu","year":"2010","journal-title":"Molecules"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.afos.2018.11.083","article-title":"The advantages and limitations of mesenchymal stem cells in clinical application for treating human diseases","volume":"4","author":"Lee","year":"2018","journal-title":"Osteoporos Sarcopenia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3727\/096368910X","article-title":"Mesenchymal stem cells","volume":"20","author":"Ding","year":"2011","journal-title":"Cell Transpl."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jcyt.2013.03.005","article-title":"Risk of tumorigenicity in mesenchymal stromal cell-based therapies--bridging scientific observations and regulatory viewpoints","volume":"15","author":"Barkholt","year":"2013","journal-title":"Cytotherapy"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1126\/science.282.5391.1145","article-title":"Embryonic stem cell lines derived from human blastocysts","volume":"282","author":"Thomson","year":"1998","journal-title":"Science"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"36","DOI":"10.7150\/ijms.21666","article-title":"Ethical and Safety Issues of Stem Cell-Based Therapy","volume":"15","author":"Volarevic","year":"2018","journal-title":"Int. J. Med. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.cell.2008.02.008","article-title":"Differentiation of embryonic stem cells to clinically relevant populations: Lessons from embryonic development","volume":"132","author":"Murry","year":"2008","journal-title":"Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.scr.2009.02.002","article-title":"Teratoma formation by human embryonic stem cells: Evaluation of essential parameters for future safety studies","volume":"2","author":"Hentze","year":"2009","journal-title":"Stem Cell Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/JCN.0b013e318197a6a5","article-title":"Introduction to stem cell therapy","volume":"24","author":"Biehl","year":"2009","journal-title":"J. Cardiovasc. Nurs."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","article-title":"Induction of pluripotent stem cells from adult human fibroblasts by defined factors","volume":"131","author":"Takahashi","year":"2007","journal-title":"Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1915872","article-title":"Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson\u2019s Disease","volume":"382","author":"Schweitzer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/nm.3267","article-title":"Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies","volume":"19","author":"Lee","year":"2013","journal-title":"Nat. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.cell.2009.02.013","article-title":"Parkinson\u2019s disease patient-derived induced pluripotent stem cells free of viral reprogramming factors","volume":"136","author":"Soldner","year":"2009","journal-title":"Cell"},{"key":"ref_32","unstructured":"Shastry, S. (2021). Personal Communication, APA Style."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40035-019-0180-x","article-title":"Replacing what\u2019s lost: A new era of stem cell therapy for Parkinson\u2019s disease","volume":"9","author":"Fan","year":"2020","journal-title":"Transl. Neurodegener."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/mds.25994","article-title":"Phenotypic variability of PINK1 expression: 12 Years\u2019 clinical follow-up of two Italian families","volume":"29","author":"Ricciardi","year":"2014","journal-title":"Mov. Disord."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Deyell, J.S., Sriparna, M., Ying, M., and Mao, X. (2023). The Interplay between alpha-Synuclein and Microglia in alpha-Synucleinopathies. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032477"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1126\/science.6823561","article-title":"Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis","volume":"219","author":"Langston","year":"1983","journal-title":"Science"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3389\/fnmol.2019.00299","article-title":"Targeting Alpha-Synuclein as a Therapy for Parkinson\u2019s Disease","volume":"12","author":"Fields","year":"2019","journal-title":"Front. Mol. Neurosci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00401-019-02010-2","article-title":"Selective vulnerability in alpha-synucleinopathies","volume":"138","author":"Brimblecombe","year":"2019","journal-title":"Acta Neuropathol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nrn2786","article-title":"Prion-like mechanisms in neurodegenerative diseases","volume":"11","author":"Frost","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neuron.2011.08.033","article-title":"Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death","volume":"72","author":"Luk","year":"2011","journal-title":"Neuron"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1038\/s41467-022-31787-2","article-title":"alpha-Synuclein fibril-specific nanobody reduces prion-like alpha-synuclein spreading in mice","volume":"13","author":"Butler","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"9441","DOI":"10.1523\/JNEUROSCI.5314-13.2014","article-title":"Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson\u2019s disease-like models","volume":"34","author":"Games","year":"2014","journal-title":"J. Neurosci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e2011196118","DOI":"10.1073\/pnas.2011196118","article-title":"Mechanistic basis for receptor-mediated pathological \u03b1-synuclein fibril cell-to-cell transmission in Parkinson\u2019s disease","volume":"118","author":"Zhang","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Mao, X., Gu, H., Kim, D., Kimura, Y., Wang, Y., Xu, E., Wang, H., Chen, C., Zhang, S., and Jia, C. (2021). Aplp1 and the Aplp1-Lag3 Complex facilitates transmission of pathologic \u03b1-synuclein. bioRxiv.","DOI":"10.1101\/2021.05.01.442157"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Chen, C., Kumbhar, R., Wang, H., Yang, X., Gadhave, K., Rastegar, C., Kimura, Y., Behensky, A., Katakam, S., and Jeong, D. (2023). Pathological Tau transmission initiated by binding lymphocyte-activation gene 3. bioRxiv.","DOI":"10.1101\/2023.05.16.541015"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"656426","DOI":"10.3389\/fncel.2021.656426","article-title":"Lymphocyte Activation Gene 3 (Lag3) Contributes to \u03b1-Synucleinopathy in \u03b1-Synuclein Transgenic Mice","volume":"15","author":"Gu","year":"2021","journal-title":"Front. Cell Neurosci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"aah3374","DOI":"10.1126\/science.aah3374","article-title":"Pathological alpha-synuclein transmission initiated by binding lymphocyte-activation gene 3","volume":"353","author":"Mao","year":"2016","journal-title":"Science"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s13760-016-0679-1","article-title":"alpha-Synuclein-carrying extracellular vesicles in Parkinson\u2019s disease: Deadly transmitters","volume":"117","author":"Chistiakov","year":"2017","journal-title":"Acta Neurol. Belg."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/jnc.15288","article-title":"Exosomes in Parkinson disease","volume":"157","author":"Pinnell","year":"2021","journal-title":"J. Neurochem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jconrel.2015.03.033","article-title":"Exosomes as drug delivery vehicles for Parkinson\u2019s disease therapy","volume":"207","author":"Haney","year":"2015","journal-title":"J. Control Release"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1002\/mds.25978","article-title":"Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice","volume":"29","author":"Cooper","year":"2014","journal-title":"Mov. Disord."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/j.ymthe.2019.08.010","article-title":"Systemic Exosomal Delivery of shRNA Minicircles Prevents Parkinsonian Pathology","volume":"27","author":"Izco","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"15012","DOI":"10.1038\/celldisc.2015.12","article-title":"Autologous iPSC-derived dopamine neuron transplantation in a nonhuman primate Parkinson\u2019s disease model","volume":"1","author":"Wang","year":"2015","journal-title":"Cell Discov."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41531-019-0105-5","article-title":"Emerging regenerative medicine and tissue engineering strategies for Parkinson\u2019s disease","volume":"6","author":"Harris","year":"2020","journal-title":"NPJ Park. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.stem.2014.09.017","article-title":"Human ESC-derived dopamine neurons show similar preclinical efficacy and potency to fetal neurons when grafted in a rat model of Parkinson\u2019s disease","volume":"15","author":"Grealish","year":"2014","journal-title":"Cell Stem Cell"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.stem.2015.01.018","article-title":"Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson\u2019s disease","volume":"16","author":"Hallett","year":"2015","journal-title":"Cell Stem Cell"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Kin, K., Yasuhara, T., Kameda, M., and Date, I. (2019). Animal Models for Parkinson\u2019s Disease Research: Trends in the 2000s. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20215402"},{"key":"ref_58","unstructured":"Cauvin, A.J., Peters, C., and Brennan, F. (2015). The nonhuman Primate in Nonclinical Drug Development and Safety Assessment, Elsevier."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/stem.1415","article-title":"Improved cell therapy protocols for Parkinson\u2019s disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons","volume":"31","author":"Sundberg","year":"2013","journal-title":"Stem Cells"},{"key":"ref_60","unstructured":"Osborn, T., Dinesh, D., Moskites, A., MacBain, Z., Moore, M., and Brekk, O. (2020). Pre-clinical studies toward autologous midbrain dopamine cell therapy for Parkinson\u2019s disease. Stem J., in press."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"15921","DOI":"10.1073\/pnas.1010209107","article-title":"Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats","volume":"107","author":"Hargus","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"5856","DOI":"10.1073\/pnas.0801677105","article-title":"Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson\u2019s disease","volume":"105","author":"Wernig","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/12\/2656\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:26:55Z","timestamp":1760131615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/12\/2656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,22]]},"references-count":62,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["pharmaceutics15122656"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics15122656","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,22]]}}}